Activity modulator, medicinal agent comprising same, use of CD300A gene-deficient mouse, and anti-CD300A antibody
AssigneeUniversity of Tsukuba
InventorsAkira Shibuya, Chigusa Oda, Satoko Tahara, Tsukasa Nabekura, Udayanga Sanath Kankanam Gamage, Haruka Miki, Syuichi Iino
Life of this patent
Estimating the term…
Abstract
The present invention aims to provide: an immunostimulant useful for maintaining, enhancing or suppressing an immune function associated with CD300a activation signaling, or an immunomodulator as an immunosuppressant useful for suppressing the immune function; use of a CD300a gene-deficient mouse for pathology analysis and the like; an anti-CD300a antibody; and the like.
Claims12
A method for treatment of a disease or disease state in which inhibitory signal transduction of a cluster of differentiation 300a (CD300a)-expressing myeloid cell is involved via an immunoreceptor tyrosine-based inhibitory motif (ITIM) of CD300a, comprising:
- administering to a subject an effective amount of a neutralizing antibody against CD300a which inhibits binding between CD300a and phosphatidyl serine;
- wherein said neutralizing antibody against CD300a suppresses inhibitory signal transduction of the CD300a-expressing myeloid cell, and
- wherein the neutralizing antibody comprises an H-chain variable region having the amino acid sequence of SEQ ID NO:
- 19 and a L-chain variable region having the amino acid sequence of SEQ ID NO:
- 20.
A method for treatment of a disease or disease state in which inhibitory signal transduction of a cluster of differentiation 300a (CD300a)-expressing myeloid cell is involved via an immunoreceptor tyrosine-based inhibitory motif (ITIM) of CD300a, comprising:
- administering to a subject an effective amount of a neutralizing antibody against CD300a which inhibits binding between CD300a and phosphatidyl serine;
- wherein said neutralizing antibody against CD300a suppresses inhibitory signal transduction of the CD300a-expressing myeloid cell, and
- wherein said neutralizing antibody against CD300a is:
- an anti-human CD300a antibody comprising:
- i) an H-chain variable region having an amino acid sequence that is the same as the amino acid sequence of SEQ ID NO:
- 19 except that 1, 2, 3, 4, or 5 amino acid(s) is/are each conservatively substituted in a region other than the complementarity determining regions of SEQ ID NO:
- 19;
- and
- ii) an L-chain variable region an amino acid sequence that is the same as the amino acid sequence of SEQ ID NO:
- 20 except that 1, 2, 3, 4, or 5 amino acid(s) is/are each conservatively substituted in a region other than the complementarity determining regions of SEQ ID NO:
- 20.
A method for treatment of an inflammatory infection, allergic disease or autoimmune disease, comprising:
- administering to a subject an effective amount of a neutralizing antibody against CD300a which inhibits binding between cluster of differentiation 300a (CD300a) and phosphatidyl serine,
- wherein the neutralizing antibody comprises an H-chain variable region having the amino acid sequence of SEQ ID NO:
- 19 and a L-chain variable region having the amino acid sequence of SEQ ID NO:
- 20.
A method for treatment of an inflammatory infection, allergic disease or autoimmune disease, comprising:
- administering to a subject an effective amount of a neutralizing antibody against CD300a which inhibits binding between cluster of differentiation 300a (CD300a) and phosphatidyl serine,
- wherein said neutralizing antibody against CD300a is:
- an anti-human CD300a antibody comprising:
- i) an H-chain variable region having an amino acid sequence that is the same as the amino acid sequence of SEQ ID NO:
- 19 except that 1, 2, 3, 4, or 5 amino acid(s) is/are each conservatively substituted in a region other than the complementarity determining regions of SEQ ID NO:
- 19;
- and
- ii) an L-chain variable region an amino acid sequence that is the same as the amino acid sequence of SEQ ID NO:
- 20 except that 1, 2, 3, 4, or 5 amino acid(s) is/are each conservatively substituted in a region other than the complementarity determining regions of SEQ ID NO:
- 20.
Dependencies are inferred from the claim text.